1. Home
  2. ANVS vs NA Comparison

ANVS vs NA Comparison

Compare ANVS & NA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Annovis Bio Inc.

ANVS

Annovis Bio Inc.

HOLD

Current Price

$2.24

Market Cap

69.1M

Sector

Health Care

ML Signal

HOLD

NA

Nano Labs Ltd

HOLD

Current Price

$2.48

Market Cap

58.5M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANVS
NA
Founded
2008
2019
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
69.1M
58.5M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
ANVS
NA
Price
$2.24
$2.48
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$13.50
N/A
AVG Volume (30 Days)
1.1M
143.4K
Earning Date
05-12-2026
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
39.39
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.54
$1.58
52 Week High
$5.50
$31.48

Technical Indicators

Market Signals
Indicator
ANVS
NA
Relative Strength Index (RSI) 55.41 51.23
Support Level $1.92 $1.61
Resistance Level $2.38 $3.35
Average True Range (ATR) 0.17 0.35
MACD 0.00 0.08
Stochastic Oscillator 69.40 67.77

Price Performance

Historical Comparison
ANVS
NA

About ANVS Annovis Bio Inc.

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

About NA Nano Labs Ltd

Nano Labs Ltd is a Web 3.0 infrastructure and product solution provider, as well as a crypto treasury company. It is focused on the development of HTC chips and HPC chips. In addition, the company has established BNB value investment and adopted BNB (a crypto token) as the primary reserve asset. Furthermore, it has launched the iPollo Claw, a dedicated hardware solution for the OpenClaw AI Agent Ecosystem. Nano Labs derives revenue mainly from its HTC and HPC offerings, which comprise Darkbird series HPC chips that feature high performance and high energy consumption efficiency, and Cuckoo series chips, used in GPUs. Geographically, the company generates maximum revenue from the People's Republic of China (PRC), and the rest from Singapore, Hong Kong, the United States, and other markets.

Share on Social Networks: